Coherus Oncology, Inc. (CHRS): Cost of Revenue
Partial revenue. In this company's filings, net income for the year ended 2025-12-31 is larger than reported revenue. The revenue it tags covers only part of its income (banks and REITs often tag only fee income this way, leaving out interest or rent), so it is not the company's whole top line. Margins on it are not computed, and it is left out of revenue rankings.
$13.81M
Year ended 2025-12-31
$15.82M
Trailing 12 months to 2026-06-30
-41.8%
3-year compound annual growth
-18.2%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $13.81M | +58.3% | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | $8.73M | -94.5% | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | $158.99M | +126.9% | 2025-03-17, From 2023-01-01 |
| 2022-12-31 | $70.08M | +21.7% | 2025-03-17, From 2022-01-01 |
| 2021-12-31 | $57.59M | +52.9% | 2024-03-15, From 2021-01-01 |
| 2020-12-31 | $37.67M | +120.6% | 2023-03-06, From 2020-01-01 |
| 2019-12-31 | $17.08M | n/a | 2022-02-23, From 2019-01-01 |